ArticleBMC infectious diseases2015
Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).Pathogens (Basel, Switzerland) · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era.Environment international · 2023Review
- Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.Gates open research · 2023Article
- Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Polio: abandoning eradication would result in rapid resurgence of an ancient scourge.BMJ global health · 2019Article
- Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.Expert review of vaccines · 2018Review
- Using integrated modeling to support the global eradication of vaccine-preventable diseases.System dynamics review · 2018Article
- Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.BMC infectious diseases · 2018Article
- The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.BMC infectious diseases · 2018Article
- Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo.Vaccine · 2017Article
- Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped.Epidemics · 2017Article
- Article
- Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.The Journal of infectious diseases · 2017Article
- Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.Journal of vaccines & vaccination · 2016Article
- Article
- Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.BMC infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) use, beginning with serotype 2-containing OPV (i.e., OPV2 cessation) followed by the remaining two OPV serotypes (i.e., OPV13 cessation). The risk of circulating vaccine-derived poliovirus (cVDPV) outbreaks after OPV cessation of any serotype depends on the serotype-specific population immunity to transmission prior to its cessation.
methodsBased on an existing integrated global model of poliovirus risk management policies, we estimate the serotype-specific OPV doses required to manage population immunity for a strategy of intensive supplemental immunization activities (SIAs) shortly before OPV cessation of each serotype. The strategy seeks to prevent any cVDPV outbreaks after OPV cessation, although actual events remain stochastic.
resultsManaging the risks of OPV cessation of any serotype depends on achieving sufficient population immunity to transmission to transmission at OPV cessation. This will require that countries with sub-optimal routine immunization coverage and/or conditions that favor poliovirus transmission conduct SIAs with homotypic OPV shortly before its planned coordinated cessation. The model suggests the need to increase trivalent OPV use in SIAs by approximately 40 % or more during the year before OPV2 cessation and to continue bOPV SIAs between the time of OPV2 cessation and OPV13 cessation.
conclusionsManaging the risks of cVDPVs in the polio endgame will require serotype-specific OPV SIAs in some areas prior to OPV cessation and lead to demands for additional doses of the vaccine in the short term that will affect managers and manufacturers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.